Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01), Zacks reports.
Actuate Therapeutics Price Performance
Shares of Actuate Therapeutics stock opened at $2.90 on Friday. The firm has a market cap of $68.76 million, a price-to-earnings ratio of -2.76 and a beta of 0.92. The stock has a 50-day simple moving average of $2.57 and a 200-day simple moving average of $4.69. Actuate Therapeutics has a 52-week low of $1.58 and a 52-week high of $11.99.
Institutional Trading of Actuate Therapeutics
A number of institutional investors have recently added to or reduced their stakes in ACTU. Barclays PLC lifted its position in shares of Actuate Therapeutics by 68.6% in the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after buying an additional 6,081 shares during the last quarter. State Street Corp boosted its stake in Actuate Therapeutics by 12.8% during the 4th quarter. State Street Corp now owns 56,290 shares of the company’s stock valued at $344,000 after purchasing an additional 6,395 shares during the period. Wells Fargo & Company MN increased its position in Actuate Therapeutics by 48.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock worth $123,000 after buying an additional 6,604 shares during the period. Deutsche Bank AG increased its position in Actuate Therapeutics by 640.0% in the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock worth $57,000 after buying an additional 8,051 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Actuate Therapeutics by 61.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,841 shares of the company’s stock worth $146,000 after buying an additional 9,076 shares during the last quarter.
Analysts Set New Price Targets
View Our Latest Research Report on ACTU
Actuate Therapeutics Company Profile
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
Featured Articles
- Five stocks we like better than Actuate Therapeutics
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
